2. Anti-infection
  3. HIV Reverse Transcriptase
  4. Zalcitabine

Zalcitabine  (Synonyms: 2',3'-Dideoxycytidine; ddC; Dideoxycytidine; ジデオキシシチジン)

製品番号: HY-17392 純度: 99.81%
COA 取扱説明書 Technical Support

Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 7481-89-2

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 60 在庫あり
Solution
10 mM * 1 mL in DMSO USD 60 在庫あり
Solid
50 mg $55 在庫あり
100 mg $77 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 14 publication(s) in Google Scholar

Other Forms of Zalcitabine:

Zalcitabine 関連抗体

Top Publications Citing Use of Products

    Zalcitabine purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 6;15(1):6685.  [Abstract]

    Expression of MT-ND1 (UT Ctrl vs. UT T132A, P<0.0001), MT-ND2, L1ORF1, and POLG1 was measured by qPCR in vector alone (Ctrl), REXO2 (WT), and REXO2 (T132A) THP-1 stable cell lines with or without Zalcitabine (4 μM) treatment.

    Zalcitabine purchased from MedChemExpress. Usage Cited in: J Cell Biol. 2023 Oct 2;222(10):e202302037.  [Abstract]

    mtDNA copy number changed during induced depletion and re-population in WT and KO HEK-293T cells. mtDNA depletion was achieved by adding 100 µM ddC to the culture medium for 4 d, and then the cells were cultured for 5 d in the absence of ddC for mtDNA recovery.

    Zalcitabine purchased from MedChemExpress. Usage Cited in: J Cell Biol. 2023 Oct 2;222(10):e202302037.  [Abstract]

    Western blot showed changes of C17orf80 protein level in control and knockdown groups during mtDNA depletion and recovery. 100 µM Zalcitabine was added to the culture medium for 4 d.

    Zalcitabine purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2207280119.  [Abstract]

    Effect of mtDNA depletion on LF2000-induced transcription of the Ifnb1 gene. DMSO and ddC (50 ng/mL)-treated Raw264.7 cells were untreated or treated with LF2000 (10 μg/mL) for 6 h, followed by qPCR analysis of the Ifnb1 gene.

    Zalcitabine purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2207280119.  [Abstract]

    Effects of mtDNA depletion on LF2000-induced activation of Syk and phosphorylation of cGAS Y201. DMSO- and ddC (50 ng/mL; 5 d)-treated Raw264.7 cells were left untreated or treated with LF2000 (20 μg/mL) for the indicated times before immunoblot analysis with the indicated antibodies.

    HIV アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    HIV HIV-1 HIV-2

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of HIV infection.

    IC50 & Target

    Target: HIV
    Cellular Effect
    Cell Line Type Value Description References
    ATH-8 cell line ED50
    0.2 3
    Compound: ddCyd
    Protection of ATH8 cells against the cytopathic effect of HIV.
    Protection of ATH8 cells against the cytopathic effect of HIV.
    		[PMID: 3497272]
    CEM-SS CC50
    > 10 3
    Compound: DDC
    Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
    Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
    		[PMID: 9240351]
    C8166 IC50
    0.125 3
    Compound: 2
    Antiviral activity against HIV-1 (RF strain) in C8166 cells
    Antiviral activity against HIV-1 (RF strain) in C8166 cells
    		[PMID: 2165161]
    C8166 IC50
    0.125 3
    Compound: 2
    Antiviral activity against HIV-1 (RF strain) in C8166 cells
    Antiviral activity against HIV-1 (RF strain) in C8166 cells
    		[PMID: 2165161]
    CEM-SS CC50
    16 3
    Compound: ddC
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    CCRF-CEM CC50
    178.8 3
    Compound: 3, ddC
    Cytotoxicity against human CEM/0 cells
    Cytotoxicity against human CEM/0 cells
    		[PMID: 24411122]
    CEM-SS CC50
    34 3
    Compound: 2, ddC
    Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
    Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
    		[PMID: 10821705]
    CCRF-CEM CC50
    178.8 3
    Compound: 3, ddC
    Cytotoxicity against human CEM/0 cells
    Cytotoxicity against human CEM/0 cells
    		[PMID: 24411122]
    CCRF-CEM EC50
    0.189 3
    Compound: ddC
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    		[PMID: 8632437]
    CEM-SS CC50
    46 3
    Compound: ddC
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    CCRF-CEM EC50
    0.189 3
    Compound: ddC
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    		[PMID: 8632437]
    CEM-SS CC50
    46 3
    Compound: ddC
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    		[PMID: 33711763]
    CCRF-CEM EC50
    0.3 3
    Compound: 2a
    Effect on HIV-induced cytopathogenesis in CEM cells.
    Effect on HIV-induced cytopathogenesis in CEM cells.
    		[PMID: 1351945]
    CCRF-CEM EC50
    0.3 3
    Compound: 2a
    Effect on HIV-induced cytopathogenesis in CEM cells.
    Effect on HIV-induced cytopathogenesis in CEM cells.
    		[PMID: 1351945]
    CCRF-CEM IC50
    47.34 3
    Compound: ddC
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    		[PMID: 8632437]
    CEM-TK(-) CC50
    7 3
    Compound: ddC
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    CCRF-CEM ED50
    1.0 x 10-8 41
    Compound: ddc
    The compound was evaluated for the activity on HIV infected CEM cells.
    The compound was evaluated for the activity on HIV infected CEM cells.
    		10.1016/S0960-894X(01)81206-3
    CCRF-CEM IC50
    1.9 3
    Compound: 3, ddC
    Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells
    Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells
    		[PMID: 24411122]
    CEM-TK(-) CC50
    8.3 3
    Compound: ddC
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    CCRF-CEM IC50
    0.022 3
    Compound: ddc
    Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells
    Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells
    		[PMID: 8145230]
    CCRF-CEM IC50
    0.05 6
    Compound: DDC
    Compound was tested for its inhibitory activity against HIV replication in CEM cells.
    Compound was tested for its inhibitory activity against HIV replication in CEM cells.
    		[PMID: 1738145]
    H9 EC50
    0.001 3
    Compound: ddC
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    		[PMID: 11430019]
    CCRF-CEM IC50
    0.05 6
    Compound: DDC
    Compound was tested for its inhibitory activity against HIV replication in CEM cells.
    Compound was tested for its inhibitory activity against HIV replication in CEM cells.
    		[PMID: 1738145]
    CCRF-CEM IC50
    0.022 3
    Compound: ddc
    Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells
    Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells
    		[PMID: 8145230]
    CCRF-CEM IC50
    0.07 3
    Compound: ddc
    Inhibitory concentration against mitochondrial DNA synthesis CEM cells
    Inhibitory concentration against mitochondrial DNA synthesis CEM cells
    		[PMID: 9438017]
    H9 EC50
    0.001 3
    Compound: ddC
    Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    		[PMID: 11430019]
    H9 EC50
    0.079 3
    Compound: dideoxycytidine
    Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique
    Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique
    		[PMID: 25587934]
    CCRF-CEM IC50
    1.9 3
    Compound: 3, ddC
    Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells
    Antiviral activity against HIV-2 ROD infected in thymidine kinase-deficient human CEM cells
    		[PMID: 24411122]
    CCRF-CEM IC50
    >100 3
    Compound: 8 (beta-L-ddC)
    Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells
    Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells
    		[PMID: 8145230]
    CCRF-CEM IC50
    10 3
    Compound: ddc
    Cytotoxicity on CEM cells
    Cytotoxicity on CEM cells
    		[PMID: 9438017]
    HepG2 CC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
    Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
    		[PMID: 25849312]
    CCRF-CEM IC50
    10 3
    Compound: ddc
    Cytotoxicity on CEM cells
    Cytotoxicity on CEM cells
    		[PMID: 9438017]
    CCRF-CEM IC50
    120 3
    Compound: 2a
    Effect on HIV-induced cytopathogenesis in CEM cells.
    Effect on HIV-induced cytopathogenesis in CEM cells.
    		[PMID: 1351945]
    HepG2 CC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method
    Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method
    		[PMID: 25849312]
    CCRF-CEM IC50
    120 3
    Compound: 2a
    Effect on HIV-induced cytopathogenesis in CEM cells.
    Effect on HIV-induced cytopathogenesis in CEM cells.
    		[PMID: 1351945]
    HepG2 IC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
    		[PMID: 28595015]
    CCRF-CEM IC50
    28 3
    Compound: ddc
    In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined
    In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined
    		[PMID: 8145230]
    CCRF-CEM IC50
    28 3
    Compound: ddc
    In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined
    In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined
    		[PMID: 8145230]
    HepG2 IC50
    < 10 3
    Compound: ddC
    Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
    Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
    		[PMID: 28595015]
    CCRF-CEM IC50
    47.34 3
    Compound: ddC
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    Anti-HIV activity against HIV-I RFII strain in CEM cell line
    		[PMID: 8632437]
    CCRF-CEM IC50
    70 3
    Compound: 8 (beta-L-ddC)
    In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined
    In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined
    		[PMID: 8145230]
    CCRF-CEM IC50
    0.07 3
    Compound: ddc
    Inhibitory concentration against mitochondrial DNA synthesis CEM cells
    Inhibitory concentration against mitochondrial DNA synthesis CEM cells
    		[PMID: 9438017]
    HepG2 IC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    		[PMID: 30653317]
    CCRF-CEM IC50
    70 3
    Compound: 8 (beta-L-ddC)
    In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined
    In vitro cytotoxicity against human CCRF-CEM T-lymphoblastic leukemia cells was determined
    		[PMID: 8145230]
    CEM-SS CC50
    34 3
    Compound: 2, ddC
    Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
    Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
    		[PMID: 10821705]
    HepG2 IC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    		[PMID: 30653317]
    CCRF-CEM IC50
    > 100 3
    Compound: 8 (beta-L-ddC)
    Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells
    Concentration of compound required to inhibit the synthesis of mitochondrial DNA (mt DNA) in human CCRF-CEM T-lymphoblastic leukemia cells
    		[PMID: 8145230]
    CEM-SS CC50
    >10 3
    Compound: DDC
    Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
    Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
    		[PMID: 9240351]
    HepG2 EC50
    1.4 3
    Compound: 2',3'-Dideoxycytidine (ddC)
    Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
    Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
    		10.1016/S0960-894X(97)00422-8
    CEM-SS CC50
    16 3
    Compound: ddC
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    HepG2 IC50
    252 3
    Compound: 2',3'-Dideoxycytidine (ddC)
    Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
    Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
    		10.1016/S0960-894X(97)00422-8
    CEM-SS CC50
    46 3
    Compound: ddC
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    HepG2 2.2.15 CC50
    233 3
    Compound: ddc
    Compound concentration that cause 50% cytotoxicity was determined by neutral red uptake in 2.2.15 Cells
    Compound concentration that cause 50% cytotoxicity was determined by neutral red uptake in 2.2.15 Cells
    		10.1016/S0960-894X(97)00001-2
    CEM-SS EC50
    0.02 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against HIV-1 strain IIIB in CEM-SS cells
    Compound was evaluated for the antiviral activity against HIV-1 strain IIIB in CEM-SS cells
    		[PMID: 9873509]
    HL-60 IC50
    100 3
    Compound: DDC
    Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
    Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
    		[PMID: 1695683]
    MT2 CC50
    4 3
    Compound: ddC
    Cytotoxicity against human MT2 cells after 5 days by MTT assay
    Cytotoxicity against human MT2 cells after 5 days by MTT assay
    		[PMID: 24900627]
    CEM-SS EC50
    0.05 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells
    Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells
    		[PMID: 9873509]
    MT4 CC50
    > 100 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    		[PMID: 33711763]
    CEM-SS EC50
    0.19 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against SIV delta in CEM-SS cells
    Compound was evaluated for the antiviral activity against SIV delta in CEM-SS cells
    		[PMID: 9873509]
    MT4 CC50
    > 100 3
    Compound: 2, ddC
    Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
    Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
    		[PMID: 10821705]
    CEM-SS CC50
    16 3
    Compound: ddC
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    CEM-SS EC50
    0.19 3
    Compound: DDC
    Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.
    Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.
    		[PMID: 9240351]
    CEM-SS EC50
    >33 3
    Compound: 2, ddC
    Effective concentration required to achieve 50% inhibition of HIV-1 181C (nevirapine-resistant HIV-1) multiplication in CEM-SS cells.
    Effective concentration required to achieve 50% inhibition of HIV-1 181C (nevirapine-resistant HIV-1) multiplication in CEM-SS cells.
    		[PMID: 10821705]
    CEM-SS CC50
    34 3
    Compound: 2, ddC
    Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
    Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
    		[PMID: 10821705]
    MT4 CC50
    > 20 6
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 27214512]
    MT4 CC50
    > 20 6
    Compound: DDN, DDC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		10.1007/s00044-013-0567-7
    CEM-SS EC50
    0.031 3
    Compound: 2, ddC
    Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.
    Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.
    		[PMID: 10821705]
    CEM-SS CC50
    46 3
    Compound: ddC
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    CEM-SS IC50
    >5 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells
    Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells
    		[PMID: 9873509]
    CEM-SS CC50
    46 3
    Compound: ddC
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    		[PMID: 33711763]
    MT4 CC50
    > 94 3
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 21872971]
    CEM-SS IC50
    61 3
    Compound: dideoxycytidine
    Cytotoxicity against human CEM-SS cells assessed as cell growth inhibition
    Cytotoxicity against human CEM-SS cells assessed as cell growth inhibition
    		[PMID: 25587934]
    MT4 CC50
    > 94.69 3
    Compound: Zalcitabine
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 21824782]
    CEM-SS CC50
    > 10 3
    Compound: DDC
    Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
    Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
    		[PMID: 9240351]
    MT4 CC50
    > 94.69 3
    Compound: DDC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22591854]
    CEM-TK(-) CC50
    7 3
    Compound: ddC
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    MT4 CC50
    > 94.69 3
    Compound: DDC
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    CEM-TK(-) CC50
    8.3 3
    Compound: ddC
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    MT4 CC50
    > 94.69 3
    Compound: DDC
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    CEM-SS EC50
    0.02 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against HIV-1 strain IIIB in CEM-SS cells
    Compound was evaluated for the antiviral activity against HIV-1 strain IIIB in CEM-SS cells
    		[PMID: 9873509]
    H9 EC50
    0.001 3
    Compound: ddC
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    		[PMID: 11430019]
    H9 EC50
    0.079 3
    Compound: dideoxycytidine
    Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique
    Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique
    		[PMID: 25587934]
    MT4 CC50
    > 94.7 3
    Compound: DDC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22405288]
    CEM-SS EC50
    0.031 3
    Compound: 2, ddC
    Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.
    Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.
    		[PMID: 10821705]
    MT4 CC50
    > 94.7 3
    Compound: DDC
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    CEM-SS EC50
    0.05 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells
    Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells
    		[PMID: 9873509]
    H9 EC50
    0.03 3
    Compound: ddC
    Inhibition of HIV-1 replication in H9 lymphocytic cells.
    Inhibition of HIV-1 replication in H9 lymphocytic cells.
    		10.1016/0960-894X(96)00096-0
    MT4 CC50
    > 95 3
    Compound: ddC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 24119448]
    CEM-SS EC50
    0.05 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against HIV-1 strain SK1 in CEM-SS cells
    Compound was evaluated for the antiviral activity against HIV-1 strain SK1 in CEM-SS cells
    		[PMID: 9873509]
    H9 IC50
    500 3
    Compound: ddC
    Cytotoxicity against H9 lymphocytic cells.
    Cytotoxicity against H9 lymphocytic cells.
    		10.1016/0960-894X(96)00096-0
    MT4 CC50
    > 95 3
    Compound: DDC
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    HEL EC50
    7.2 3
    Compound: Zalcitabine
    Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 27742238]
    CEM-SS EC50
    0.19 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against SIV delta in CEM-SS cells
    Compound was evaluated for the antiviral activity against SIV delta in CEM-SS cells
    		[PMID: 9873509]
    HeLa IC50
    1.4 3
    Compound: ddC
    Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    MT4 CC50
    > 95 3
    Compound: DDC
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    CEM-SS EC50
    0.19 3
    Compound: DDC
    Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.
    Concentration required to achieve 50% protection of CEM-SS cells against the cytopathic effect of HIV-1.
    		[PMID: 9240351]
    HeLa IC50
    38 3
    Compound: Beta-D-dd (table 3)
    In vitro antiviral activity against HIV in HeLa CD4 cells
    In vitro antiviral activity against HIV in HeLa CD4 cells
    		10.1016/0960-894X(95)00472-6
    MT4 CC50
    > 95 3
    Compound: DDC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23084898]
    CEM-SS EC50
    > 33 3
    Compound: 2, ddC
    Effective concentration required to achieve 50% inhibition of HIV-1 181C (nevirapine-resistant HIV-1) multiplication in CEM-SS cells.
    Effective concentration required to achieve 50% inhibition of HIV-1 181C (nevirapine-resistant HIV-1) multiplication in CEM-SS cells.
    		[PMID: 10821705]
    Hepatoma cell line ED50
    0.01 3
    Compound: 8 (beta-L-ddC)
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    		[PMID: 8145230]
    MT4 CC50
    > 95 3
    Compound: DDC
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    		[PMID: 22883027]
    MT4 IC50
    0.04 6
    Compound: ddC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 21658957]
    Hepatoma cell line ED50
    2.8 3
    Compound: ddc
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    		[PMID: 8145230]
    CEM-SS IC50
    61 3
    Compound: dideoxycytidine
    Cytotoxicity against human CEM-SS cells assessed as cell growth inhibition
    Cytotoxicity against human CEM-SS cells assessed as cell growth inhibition
    		[PMID: 25587934]
    Hepatoma cell line ED50
    5 3
    Compound: 9 (alpha- L- ddC)
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    		[PMID: 8145230]
    MT4 IC50
    0.043 6
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 21658957]
    CEM-SS IC50
    > 5 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells
    Compound was evaluated for the antiviral activity against HIV-1 strain RF in CEM-SS cells
    		[PMID: 9873509]
    HepG2 CC50
    <10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
    Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
    		[PMID: 25849312]
    MT4 EC50
    0.1 6
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 12444692]
    CEM-SS IC50
    > 5 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against HIV-1 strain SK1 in CEM-SS cells
    Compound was evaluated for the antiviral activity against HIV-1 strain SK1 in CEM-SS cells
    		[PMID: 9873509]
    HepG2 EC50
    1.5 3
    Compound: ddc
    Compound concentration required to inhibit 50% of extracellular replicating HBV (Hepatitis B virus) virion in human hepatoma cell line 2.2.15
    Compound concentration required to inhibit 50% of extracellular replicating HBV (Hepatitis B virus) virion in human hepatoma cell line 2.2.15
    		10.1016/S0960-894X(97)00001-2
    MT4 EC50
    0.1 6
    Compound: ddC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 12444692]
    CEM-SS IC50
    > 5 3
    Compound: 2',3'-dideoxy cytidine, ddC
    Compound was evaluated for the antiviral activity against SIV delta in CEM-SS cells
    Compound was evaluated for the antiviral activity against SIV delta in CEM-SS cells
    		[PMID: 9873509]
    HepG2 EC50
    3.2 3
    Compound: ddc
    Compound concentration required to inhibit 50% of intracellular replicating HBV (Hepatitis B virus) RI in human hepatoma cell line 2.2.15
    Compound concentration required to inhibit 50% of intracellular replicating HBV (Hepatitis B virus) RI in human hepatoma cell line 2.2.15
    		10.1016/S0960-894X(97)00001-2
    MT4 IC50
    0.16 6
    Compound: DDN, DDC
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		10.1007/s00044-013-0567-7
    CEM-TK(-) CC50
    7 3
    Compound: ddC
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    MT4 EC50
    0.16 6
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    		[PMID: 27214512]
    CEM-TK(-) CC50
    8.3 3
    Compound: ddC
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    HepG2 EC50
    1.4 3
    Compound: 2',3'-Dideoxycytidine (ddC)
    Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
    Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
    		10.1016/S0960-894X(97)00422-8
    MT4 IC50
    0.19 6
    Compound: DDN, DDC
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		10.1007/s00044-013-0567-7
    HepG2 IC50
    2.1 6
    Compound: ddC
    Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.
    Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.
    		[PMID: 7562929]
    HepG2 IC50
    >37 3
    Compound: Dideoxycytidine
    Concentration required to inhibit 50% of host cell replication in human hepatoma (2.2.15) cells used against HBV studies
    Concentration required to inhibit 50% of host cell replication in human hepatoma (2.2.15) cells used against HBV studies
    		[PMID: 10999490]
    MT4 EC50
    0.19 6
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    		[PMID: 27214512]
    HepG2 IC50
    <10 3
    Compound: ddC
    Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
    Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
    		[PMID: 28595015]
    MT4 EC50
    0.236 3
    Compound: DDC
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).
    		[PMID: 1695683]
    HepG2 IC50
    252 3
    Compound: 2',3'-Dideoxycytidine (ddC)
    Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
    Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
    		10.1016/S0960-894X(97)00422-8
    MT4 EC50
    0.24 3
    Compound: DDC
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay
    		[PMID: 1695683]
    HepG2 IC50
    >100 3
    Compound: Beta-D-dd (table 3)
    In vitro antiviral activity against HBV in Hep G2 cells
    In vitro antiviral activity against HBV in Hep G2 cells
    		10.1016/0960-894X(95)00472-6
    MT4 EC50
    0.4 3
    Compound: ddC
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 23419738]
    HepG2 IC50
    1.4 3
    Compound: ddc
    Inhibitory concentration against hepatitis B virus infected 2.2.15 cells
    Inhibitory concentration against hepatitis B virus infected 2.2.15 cells
    		[PMID: 9438017]
    MT4 EC50
    0.4 3
    Compound: ddC
    Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 23419738]
    HepG2 IC50
    <10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    		[PMID: 30653317]
    MT4 EC50
    0.46 3
    Compound: DDC
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    0.57 3
    Compound: DDC
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    HepG2 2.2.15 CC50
    233 3
    Compound: ddc
    Compound concentration that cause 50% cytotoxicity was determined by neutral red uptake in 2.2.15 Cells
    Compound concentration that cause 50% cytotoxicity was determined by neutral red uptake in 2.2.15 Cells
    		10.1016/S0960-894X(97)00001-2
    H9 EC50
    0.001 3
    Compound: ddC
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    		[PMID: 11430019]
    HL-60 IC50
    100 3
    Compound: DDC
    Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
    Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
    		[PMID: 1695683]
    MT4 EC50
    0.75 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    H9 EC50
    0.001 3
    Compound: ddC
    Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
    		[PMID: 11430019]
    MT4 EC50
    88 1
    Compound: ddC
    Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay
    Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay
    		[PMID: 11459656]
    H9 EC50
    0.03 3
    Compound: ddC
    Inhibition of HIV-1 replication in H9 lymphocytic cells.
    Inhibition of HIV-1 replication in H9 lymphocytic cells.
    		10.1016/0960-894X(96)00096-0
    MT4 EC50
    0.88 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT2 CC50
    4 3
    Compound: ddC
    Cytotoxicity against human MT2 cells after 5 days by MTT assay
    Cytotoxicity against human MT2 cells after 5 days by MTT assay
    		[PMID: 24900627]
    MT4 EC50
    1 3
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    H9 EC50
    0.079 3
    Compound: dideoxycytidine
    Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique
    Antiviral activity against HIV1 infected in human H9 cells assessed as protection against virus-induced cytopathic effect by tetrazolium reduction based colorimetric technique
    		[PMID: 25587934]
    MT2 EC50
    0.331 3
    Compound: ddC
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1 3
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    H9 IC50
    500 3
    Compound: ddC
    Cytotoxicity against H9 lymphocytic cells.
    Cytotoxicity against H9 lymphocytic cells.
    		10.1016/0960-894X(96)00096-0
    MT2 EC50
    0.994 3
    Compound: ddC
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.04 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    HEL EC50
    7.2 3
    Compound: Zalcitabine
    Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    Antiviral activity against Human adenovirus 2 infected in HEL cells assessed as inhibition of virus-induced cytopathicity
    		[PMID: 27742238]
    MT2 EC50
    1.562 3
    Compound: ddC
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.28 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    MT4 EC50
    1.3 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    MT2 EC50
    0.9 3
    Compound: ddC
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    		[PMID: 8632437]
    MT2 EC50
    0.29 6
    Compound: DDC
    Effective concentration that increases formazan production in infected MT-2 cells
    Effective concentration that increases formazan production in infected MT-2 cells
    		[PMID: 2296018]
    MT4 EC50
    1.3 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT2 ED50
    1.5 3
    Compound: ddc
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    		[PMID: 8145230]
    MT4 EC50
    1.37 3
    Compound: DDC; dideoxycytidine
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT2 ED50
    5 3
    Compound: 8 (beta-L-ddC)
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    		[PMID: 8145230]
    MT4 EC50
    1.39 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    HL-60 IC50
    100 3
    Compound: DDC
    Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
    Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
    		[PMID: 1695683]
    MT2 ED50
    >100 3
    Compound: 9 (alpha- L- ddC)
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    		[PMID: 8145230]
    MT4 EC50
    1.4 3
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 24119448]
    HeLa IC50
    1.4 3
    Compound: ddC
    Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 infected in human HeLa P4/R5 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    MT2 IC50
    134.93 3
    Compound: ddC
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.468 3
    Compound: Zalcitabine
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    HeLa IC50
    38 3
    Compound: Beta-D-dd (table 3)
    In vitro antiviral activity against HIV in HeLa CD4 cells
    In vitro antiviral activity against HIV in HeLa CD4 cells
    		10.1016/0960-894X(95)00472-6
    MT2 IC50
    212.1 3
    Compound: ddC
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.56 3
    Compound: Zalcitabine
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT2 IC50
    258.97 3
    Compound: ddC
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.61 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    1.67 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT2 IC50
    83.8 3
    Compound: ddC
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    		[PMID: 8632437]
    MT2 IC50
    0.13 3
    Compound: ddC
    Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    MT4 EC50
    1.7 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT2 IC50
    0.44 6
    Compound: DDC
    Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.
    Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.
    		[PMID: 1738145]
    MT4 EC50
    1.7 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 CC50
    10.66 6
    Compound: ddC
    Toxicity against human MT4 cells by MTT assay
    Toxicity against human MT4 cells by MTT assay
    		[PMID: 21658957]
    MT2 IC50
    44 6
    Compound: DDC
    Inhibitory concentration that reduces formazan production in infected MT-2 cells.
    Inhibitory concentration that reduces formazan production in infected MT-2 cells.
    		[PMID: 2296018]
    MT4 CC50
    141 3
    Compound: ddC
    Concentration required to cause death of MT-4 cells was determined in vitro
    Concentration required to cause death of MT-4 cells was determined in vitro
    		[PMID: 14971898]
    MT4 EC50
    1041.6 1
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 CC50
    11 6
    Compound: ddC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 12444692]
    MT4 CC50
    30 3
    Compound: D4C
    Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.
    Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.
    		[PMID: 1495007]
    MT4 CC50
    >100 3
    Compound: 2, ddC
    Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
    Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
    		[PMID: 10821705]
    MT4 CC50
    130 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    MT4 EC50
    1394.28 1
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 CC50
    14 3
    Compound: ddC
    Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I
    Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I
    		[PMID: 11459656]
    HepG2 CC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
    Mitochondrial toxicity in human HepG2 cells assessed as effect on mitochondrial cytochrome c oxidase subunit 2 DNA level incubated for 14 days by real-time PCR method
    		[PMID: 25849312]
    MT4 CC50
    40 3
    Compound: ddCyd
    Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 2479745]
    MT4 CC50
    180 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    HepG2 CC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method
    Mitochondrial toxicity in human HepG2 cells assessed as effect on nuclear beta-actin DNA level incubated for 14 days by real-time PCR method
    		[PMID: 25849312]
    MT4 EC50
    2.4 3
    Compound: 2, ddC
    Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay
    Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay
    		[PMID: 10821705]
    MT4 CC50
    40 3
    Compound: DDC
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 1992136]
    MT4 CC50
    30 3
    Compound: D4C
    Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.
    Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.
    		[PMID: 1495007]
    MT4 CC50
    >95 3
    Compound: DDC
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    MT4 IC50
    313 3
    Compound: DDC
    Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.
    Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.
    		[PMID: 1695683]
    MT4 CC50
    >94.69 3
    Compound: DDC
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    MT4 CC50
    324.8 3
    Compound: 3, ddC
    Cytotoxicity against human MT4 cells
    Cytotoxicity against human MT4 cells
    		[PMID: 24411122]
    MT4 EC50
    33 3
    Compound: ddC
    Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method
    Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method
    		[PMID: 11958995]
    HepG2 EC50
    1.4 3
    Compound: 2',3'-Dideoxycytidine (ddC)
    Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
    Effective concentration necessary to decrease extracellular Hepatitis B virus DNA levels by 50% in human hepatoblastoma cell line (2.2.15 cells) in vitro
    		10.1016/S0960-894X(97)00422-8
    MT4 CC50
    >94.69 3
    Compound: Zalcitabine
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 CC50
    40 3
    Compound: ddCyd
    Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 2479745]
    HepG2 EC50
    1.5 3
    Compound: ddc
    Compound concentration required to inhibit 50% of extracellular replicating HBV (Hepatitis B virus) virion in human hepatoma cell line 2.2.15
    Compound concentration required to inhibit 50% of extracellular replicating HBV (Hepatitis B virus) virion in human hepatoma cell line 2.2.15
    		10.1016/S0960-894X(97)00001-2
    MT4 CC50
    40 3
    Compound: DDC
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 1992136]
    MT4 CC50
    11 6
    Compound: ddC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 12444692]
    HepG2 EC50
    3.2 3
    Compound: ddc
    Compound concentration required to inhibit 50% of intracellular replicating HBV (Hepatitis B virus) RI in human hepatoma cell line 2.2.15
    Compound concentration required to inhibit 50% of intracellular replicating HBV (Hepatitis B virus) RI in human hepatoma cell line 2.2.15
    		10.1016/S0960-894X(97)00001-2
    MT4 CC50
    >94.69 3
    Compound: DDC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 CC50
    48 3
    Compound: ddC
    Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method
    Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method
    		[PMID: 11958995]
    HepG2 IC50
    1.4 3
    Compound: ddc
    Inhibitory concentration against hepatitis B virus infected 2.2.15 cells
    Inhibitory concentration against hepatitis B virus infected 2.2.15 cells
    		[PMID: 9438017]
    MT4 CC50
    >94.7 3
    Compound: DDC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 CC50
    75.2 3
    Compound: ddC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23419738]
    HepG2 IC50
    2.1 6
    Compound: ddC
    Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.
    Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.
    		[PMID: 7562929]
    MT4 CC50
    94.7 3
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 24055077]
    HepG2 IC50
    252 3
    Compound: 2',3'-Dideoxycytidine (ddC)
    Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
    Cytotoxicity towards human hepatoblastoma cell line (2.2.15 cells) measured by inhibition of neutral red dye uptake in vitro
    		10.1016/S0960-894X(97)00422-8
    MT4 CC50
    >95 3
    Compound: ddC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 24119448]
    HepG2 IC50
    < 10 3
    Compound: ddC
    Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
    Cytotoxicity against human HepG2 cells assessed as inhibition of nuclear DNA levels measured on day 14 by RT-PCR method
    		[PMID: 28595015]
    Vero IC50
    0.02 6
    Compound: ddC
    Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells
    Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells
    		[PMID: 9548818]
    MT4 CC50
    94.7 3
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 CC50
    >94 3
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 21872971]
    HepG2 IC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA levels measured on day 14 by RT-PCR method
    		[PMID: 28595015]
    MT4 CC50
    >20 6
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 27214512]
    HepG2 IC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of cytochrome c oxidase subunit 2 DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    		[PMID: 30653317]
    HepG2 IC50
    < 10 3
    Compound: ddC
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    Mitochondrial toxicity in human HepG2 cells assessed as inhibition of nuclear ribosomal-DNA level followed by medium plus drugs replenishment every 3 to 4 days for 14 days relative to control
    		[PMID: 30653317]
    MT4 CC50
    180 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    MT4 CC50
    130 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    HepG2 IC50
    > 100 3
    Compound: Beta-D-dd (table 3)
    In vitro antiviral activity against HBV in Hep G2 cells
    In vitro antiviral activity against HBV in Hep G2 cells
    		10.1016/0960-894X(95)00472-6
    MT4 CC50
    >100 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    		[PMID: 33711763]
    HepG2 IC50
    > 37 3
    Compound: Dideoxycytidine
    Concentration required to inhibit 50% of host cell replication in human hepatoma (2.2.15) cells used against HBV studies
    Concentration required to inhibit 50% of host cell replication in human hepatoma (2.2.15) cells used against HBV studies
    		[PMID: 10999490]
    MT4 CC50
    75.2 3
    Compound: ddC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23419738]
    MT4 CC50
    >20 6
    Compound: DDN, DDC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 CC50
    >95 3
    Compound: DDC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23084898]
    MT4 CC50
    >94.7 3
    Compound: DDC; dideoxycytidine
    Cytotoxicity against mock-infected human MT4 cells
    Cytotoxicity against mock-infected human MT4 cells
    		[PMID: 27234889]
    MT4 CC50
    >94.7 3
    Compound: DDC
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 CC50
    >95 3
    Compound: DDC
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    		[PMID: 22883027]
    MT4 CC50
    48 3
    Compound: ddC
    Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method
    Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method
    		[PMID: 11958995]
    MT4 CC50
    10.66 6
    Compound: ddC
    Toxicity against human MT4 cells by MTT assay
    Toxicity against human MT4 cells by MTT assay
    		[PMID: 21658957]
    HepG2 2.2.15 CC50
    233 3
    Compound: ddc
    Compound concentration that cause 50% cytotoxicity was determined by neutral red uptake in 2.2.15 Cells
    Compound concentration that cause 50% cytotoxicity was determined by neutral red uptake in 2.2.15 Cells
    		10.1016/S0960-894X(97)00001-2
    MT4 EC50
    33 3
    Compound: ddC
    Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method
    Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method
    		[PMID: 11958995]
    Hepatoma cell line ED50
    0.01 3
    Compound: 8 (beta-L-ddC)
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    		[PMID: 8145230]
    MT4 EC50
    0.236 3
    Compound: DDC
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).
    		[PMID: 1695683]
    Hepatoma cell line ED50
    2.8 3
    Compound: ddc
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    		[PMID: 8145230]
    Hepatoma cell line ED50
    5 3
    Compound: 9 (alpha- L- ddC)
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    The compound was tested for antiviral activity against Hepatitis B virus in human hepatoma cells.
    		[PMID: 8145230]
    MT4 EC50
    0.24 3
    Compound: DDC
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay
    		[PMID: 1695683]
    MT2 CC50
    4 3
    Compound: ddC
    Cytotoxicity against human MT2 cells after 5 days by MTT assay
    Cytotoxicity against human MT2 cells after 5 days by MTT assay
    		[PMID: 24900627]
    MT4 EC50
    1.39 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    0.1 6
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 12444692]
    MT2 EC50
    0.29 6
    Compound: DDC
    Effective concentration that increases formazan production in infected MT-2 cells
    Effective concentration that increases formazan production in infected MT-2 cells
    		[PMID: 2296018]
    MT4 EC50
    1 3
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    MT2 EC50
    0.331 3
    Compound: ddC
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.37 3
    Compound: DDC; dideoxycytidine
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT2 EC50
    0.9 3
    Compound: ddC
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1 3
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT2 EC50
    0.994 3
    Compound: ddC
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    		[PMID: 8632437]
    MT2 EC50
    1.562 3
    Compound: ddC
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.04 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    MT4 EC50
    0.75 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT2 ED50
    1.5 3
    Compound: ddc
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    		[PMID: 8145230]
    MT4 EC50
    1.4 3
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 24119448]
    MT2 ED50
    5 3
    Compound: 8 (beta-L-ddC)
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    		[PMID: 8145230]
    MT4 EC50
    0.16 6
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    		[PMID: 27214512]
    MT2 ED50
    > 100 3
    Compound: 9 (alpha- L- ddC)
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    The compound was tested for antiviral activity against HIV-1 in MT-2 cells
    		[PMID: 8145230]
    MT2 IC50
    0.13 3
    Compound: ddC
    Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication
    Antiviral activity against HIV1 infected in human MT2 cells assessed as inhibition of viral replication
    		[PMID: 19596885]
    MT4 EC50
    1.7 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    1.67 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT2 IC50
    0.44 6
    Compound: DDC
    Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.
    Compound was tested for its inhibitory activity against HIV replication in MT-2 cells.
    		[PMID: 1738145]
    MT4 EC50
    1.3 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    MT2 IC50
    134.93 3
    Compound: ddC
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    Anti-HIV activity against HIV-I A17 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.3 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT2 IC50
    212.1 3
    Compound: ddC
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    Anti-HIV activity against HIV-I G910-6 strain in MT2 cell line
    		[PMID: 8632437]
    MT2 IC50
    258.97 3
    Compound: ddC
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    Anti-HIV activity against HIV-I H112-2 strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    1.28 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    MT4 EC50
    0.88 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT2 IC50
    44 6
    Compound: DDC
    Inhibitory concentration that reduces formazan production in infected MT-2 cells.
    Inhibitory concentration that reduces formazan production in infected MT-2 cells.
    		[PMID: 2296018]
    MT2 IC50
    83.8 3
    Compound: ddC
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    Anti-HIV activity against HIV-I IIIB strain in MT2 cell line
    		[PMID: 8632437]
    MT4 EC50
    0.19 6
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    		[PMID: 27214512]
    MT4 EC50
    1.61 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    1.7 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    0.4 3
    Compound: ddC
    Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 23419738]
    MT4 CC50
    10.66 6
    Compound: ddC
    Toxicity against human MT4 cells by MTT assay
    Toxicity against human MT4 cells by MTT assay
    		[PMID: 21658957]
    MT4 CC50
    11 6
    Compound: ddC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 12444692]
    MT4 EC50
    1.56 3
    Compound: Zalcitabine
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    0.46 3
    Compound: DDC
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 CC50
    130 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of AZT by MTT assay
    		[PMID: 33711763]
    MT4 EC50
    1.468 3
    Compound: Zalcitabine
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 CC50
    14 3
    Compound: ddC
    Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I
    Cytotoxic concentration of compound required to reduce the viability of mock infected MT-4 cells on the MTT assay in test I
    		[PMID: 11459656]
    MT4 EC50
    0.57 3
    Compound: DDC
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 CC50
    141 3
    Compound: ddC
    Concentration required to cause death of MT-4 cells was determined in vitro
    Concentration required to cause death of MT-4 cells was determined in vitro
    		[PMID: 14971898]
    MT4 EC50
    0.3 3
    Compound: ddCyd
    Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1
    Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1
    		[PMID: 2479745]
    MT4 CC50
    180 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33711763]
    MT4 CC50
    30 3
    Compound: D4C
    Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.
    Concentration required to reduce the number of viable uninfected MT-4 cells by 50%.
    		[PMID: 1495007]
    MT4 EC50
    0.91 3
    Compound: D4C
    Concentration required to protect 50% of HIV-1 infected MT-4 cells against viral cytopathicity.
    Concentration required to protect 50% of HIV-1 infected MT-4 cells against viral cytopathicity.
    		[PMID: 1495007]
    MT4 EC50
    0.69 3
    Compound: D4C
    Concentration required to protect 50% of HIV-2 infected MT-4 cells against viral cytopathicity.
    Concentration required to protect 50% of HIV-2 infected MT-4 cells against viral cytopathicity.
    		[PMID: 1495007]
    MT4 CC50
    324.8 3
    Compound: 3, ddC
    Cytotoxicity against human MT4 cells
    Cytotoxicity against human MT4 cells
    		[PMID: 24411122]
    MT4 EC50
    2.4 3
    Compound: 2, ddC
    Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay
    Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay
    		[PMID: 10821705]
    MT4 CC50
    40 3
    Compound: DDC
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 1992136]
    MT4 EC50
    0.3 3
    Compound: DDC
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).
    		[PMID: 1992136]
    MT4 CC50
    40 3
    Compound: ddCyd
    Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%
    Cytotoxic concentration of compound required to reduce the viability of mock-infected MT-4 cells by 50%
    		[PMID: 2479745]
    MT4 EC50
    1.04 3
    Compound: ddC
    Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro
    Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro
    		[PMID: 14971898]
    MT4 CC50
    48 3
    Compound: ddC
    Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method
    Cytotoxicity based on the reduction of the viability of mock-infected MT-4 cells using the MTT method
    		[PMID: 11958995]
    MT4 ED50
    0.3 3
    Compound: ddCyd
    Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV
    Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV
    		[PMID: 2342078]
    MT4 CC50
    75.2 3
    Compound: ddC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23419738]
    MT4 CC50
    94.7 3
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 ED50
    0.011 6
    Compound: DDC
    In vitro antiviral activity against HIV-1 in MT-4 Cell
    In vitro antiviral activity against HIV-1 in MT-4 Cell
    		[PMID: 1588565]
    MT4 CC50
    > 100 3
    Compound: 2, ddC
    Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
    Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
    		[PMID: 10821705]
    MT4 IC50
    1 3
    Compound: 3, ddC
    Antiviral activity against HIV-1 3B infected in human MT4 cells
    Antiviral activity against HIV-1 3B infected in human MT4 cells
    		[PMID: 24411122]
    MT4 IC50
    0.043 6
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 21658957]
    MT4 CC50
    > 100 3
    Compound: ddC
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days in presence of ddA by MTT assay
    		[PMID: 33711763]
    MT4 CC50
    > 20 6
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 27214512]
    MT4 IC50
    0.16 6
    Compound: DDN, DDC
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 IC50
    1.9 3
    Compound: 3, ddC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells
    Antiviral activity against HIV-2 ROD infected in human MT4 cells
    		[PMID: 24411122]
    MT4 CC50
    > 20 6
    Compound: DDN, DDC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 IC50
    0.04 6
    Compound: ddC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 21658957]
    MT4 CC50
    > 94 3
    Compound: DDC
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 IC50
    0.19 6
    Compound: DDN, DDC
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 CC50
    > 94.69 3
    Compound: DDC
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    MT4 IC50
    313 3
    Compound: DDC
    Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.
    Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.
    		[PMID: 1695683]
    MT4 CC50
    > 94.69 3
    Compound: DDC
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    MT4 IC50
    1.6 3
    Compound: 2',3'-dideoxy cytidine
    Potency against non nucleoside reverse transcriptor was determined in MT-4 cells
    Potency against non nucleoside reverse transcriptor was determined in MT-4 cells
    		[PMID: 15109677]
    MT4 CC50
    > 94.69 3
    Compound: DDC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 EC50
    1041.6 1
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 CC50
    > 94.69 3
    Compound: Zalcitabine
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    1394.28 1
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 CC50
    > 94.7 3
    Compound: DDC
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    Vero CC50
    0.49 6
    Compound: ddC
    Cytotoxic concentration to uninfected vero cells
    Cytotoxic concentration to uninfected vero cells
    		[PMID: 9548818]
    MT4 CC50
    > 94.7 3
    Compound: DDC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22405288]
    Vero IC50
    0.02 6
    Compound: ddC
    Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells
    Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells
    		[PMID: 9548818]
    MT4 CC50
    > 94.7 3
    Compound: DDC; dideoxycytidine
    Cytotoxicity against mock-infected human MT4 cells
    Cytotoxicity against mock-infected human MT4 cells
    		[PMID: 27234889]
    MT4 CC50
    > 95 3
    Compound: DDC
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    		[PMID: 22883027]
    MT4 CC50
    > 95 3
    Compound: DDC
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23084898]
    MT4 CC50
    > 95 3
    Compound: DDC
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    MT4 CC50
    > 95 3
    Compound: DDC
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    MT4 CC50
    > 95 3
    Compound: ddC
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 24119448]
    MT4 EC50
    0.16 6
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    		[PMID: 27214512]
    MT4 EC50
    0.19 6
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay
    		[PMID: 27214512]
    MT4 EC50
    0.1 6
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 12444692]
    MT4 EC50
    0.1 6
    Compound: ddC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 12444692]
    MT4 EC50
    0.236 3
    Compound: DDC
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the P24 antigen enzyme-linked immunosorbent assay (ELISA).
    		[PMID: 1695683]
    MT4 EC50
    0.24 3
    Compound: DDC
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay
    AntiHIV-1 activity measured in MT-4 cells at 5 to 6 different concentrations, using the reverse transcriptase (RT) assay
    		[PMID: 1695683]
    MT4 EC50
    0.3 3
    Compound: DDC
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).
    Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 (HTLV-IIIB).
    		[PMID: 1992136]
    MT4 EC50
    0.3 3
    Compound: ddCyd
    Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1
    Concentration required to achieve 50% protection of MT-4 cells against cytopathic effect of HIV-1
    		[PMID: 2479745]
    MT4 EC50
    0.4 3
    Compound: ddC
    Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 23419738]
    MT4 EC50
    0.4 3
    Compound: ddC
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 23419738]
    MT4 EC50
    0.46 3
    Compound: DDC
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    0.57 3
    Compound: DDC
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    0.69 3
    Compound: D4C
    Concentration required to protect 50% of HIV-2 infected MT-4 cells against viral cytopathicity.
    Concentration required to protect 50% of HIV-2 infected MT-4 cells against viral cytopathicity.
    		[PMID: 1495007]
    MT4 EC50
    0.75 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.88 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.91 3
    Compound: D4C
    Concentration required to protect 50% of HIV-1 infected MT-4 cells against viral cytopathicity.
    Concentration required to protect 50% of HIV-1 infected MT-4 cells against viral cytopathicity.
    		[PMID: 1495007]
    MT4 EC50
    1 3
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT4 EC50
    1 3
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    MT4 EC50
    1.04 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    MT4 EC50
    1.04 3
    Compound: ddC
    Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro
    Effective concentration to inhibit HIV-1 IIIB cytopathicity in MT-4 cells was determined in vitro
    		[PMID: 14971898]
    MT4 EC50
    1.28 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    MT4 EC50
    1.3 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT4 EC50
    1.3 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    MT4 EC50
    1.37 3
    Compound: DDC; dideoxycytidine
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT4 EC50
    1.39 3
    Compound: DDC
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    1.4 3
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 24119448]
    MT4 EC50
    1.468 3
    Compound: Zalcitabine
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    1.56 3
    Compound: Zalcitabine
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    1.61 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    1.67 3
    Compound: DDC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 EC50
    1.7 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-2 ROD infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    1.7 3
    Compound: DDC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    1041.6 1
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 EC50
    1394.28 1
    Compound: DDC
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 EC50
    2.4 3
    Compound: 2, ddC
    Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay
    Effective concentration required to achieve 50% inhibition of HIV-1 IIIB multiplication in hT4 lymphoblastoid MT-4 cells using MTT assay
    		[PMID: 10821705]
    MT4 EC50
    33 3
    Compound: ddC
    Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method
    Anti-HIV activity based on the protection against HIV-induced cytopathogenicity in MT-4 cells using MTT method
    		[PMID: 11958995]
    MT4 EC50
    88 1
    Compound: ddC
    Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay
    Effective concentration for 50% protection of HIV-induced cytopathogenicity in MT-4 cells on the MTT assay
    		[PMID: 11459656]
    MT4 ED50
    0.011 6
    Compound: DDC
    In vitro antiviral activity against HIV-1 in MT-4 Cell
    In vitro antiviral activity against HIV-1 in MT-4 Cell
    		[PMID: 1588565]
    MT4 ED50
    0.3 3
    Compound: ddCyd
    Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV
    Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV
    		[PMID: 2342078]
    MT4 IC50
    0.043 6
    Compound: ddC
    Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells coinjected with HTLV1 assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 21658957]
    MT4 IC50
    0.04 6
    Compound: ddC
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 21658957]
    MT4 IC50
    0.16 6
    Compound: DDN, DDC
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 IC50
    0.19 6
    Compound: DDN, DDC
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		10.1007/s00044-013-0567-7
    MT4 IC50
    1 3
    Compound: 3, ddC
    Antiviral activity against HIV-1 3B infected in human MT4 cells
    Antiviral activity against HIV-1 3B infected in human MT4 cells
    		[PMID: 24411122]
    MT4 IC50
    1.6 3
    Compound: 2',3'-dideoxy cytidine
    Potency against non nucleoside reverse transcriptor was determined in MT-4 cells
    Potency against non nucleoside reverse transcriptor was determined in MT-4 cells
    		[PMID: 15109677]
    MT4 IC50
    1.9 3
    Compound: 3, ddC
    Antiviral activity against HIV-2 ROD infected in human MT4 cells
    Antiviral activity against HIV-2 ROD infected in human MT4 cells
    		[PMID: 24411122]
    MT4 IC50
    313 3
    Compound: DDC
    Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.
    Cytotoxicity was tested in MT-4 cells by the XTT-microculture tetrazolium assay.
    		[PMID: 1695683]
    MT4 IC50
    1.0 x 10-6 41
    Compound: 1 (DDC)
    Growth inhibition of HIV-1 in human lymphocyte MT-4 cells
    Growth inhibition of HIV-1 in human lymphocyte MT-4 cells
    		[PMID: 8388473]
    Vero CC50
    0.49 6
    Compound: ddC
    Cytotoxic concentration to uninfected vero cells
    Cytotoxic concentration to uninfected vero cells
    		[PMID: 9548818]
    Vero IC50
    0.02 6
    Compound: ddC
    Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells
    Inhibition of Tomioka strain of herpes simplex virus( Tomioka strain of HSV-1) by quantitative CPE reduction assay in vero cells
    		[PMID: 9548818]
    体外実験

    Zalcitabine is a dideoxynucleoside antiretroviral agent that is phosphorylated to the active metabolite 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) within both uninfected and HIV-infected cells. At therapeutic concentrations, ddCTP inhibits HIV replication by inhibiting the enzyme reverse transcriptase and terminating elongation of the proviral DNA chain[1]. Zalcitabine exhibits the inhibition effect on the cellular uptake of [3H]-PAH in CHO/hOAT1 cells with an IC50 value of 1.23 mM. Furthermore, the cellular uptake of zalcitabine increased threefold with the enhancement of hOATI activity in CHO/hOAT1 cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Zalcitabine 関連抗体
    臨床実験
    分子量

    211.22

    分子式

    C9H13N3O3
    CAS 番号
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    OC[C@@H]1CC[C@H](N2C=CC(N)=NC2=O)O1
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : 62.5 mg/mL (295.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : ≥ 25 mg/mL (118.36 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 4.7344 mL 23.6719 mL 47.3438 mL
    5 mM 0.9469 mL 4.7344 mL 9.4688 mL
    10 mM 0.4734 mL 2.3672 mL 4.7344 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (9.85 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (9.85 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    純度とドキュメンテーション

    純度: 99.81%

    COA (252 KB) HNMR (117 KB) RP-HPLC (103 KB) LCMS (98 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 4.7344 mL 23.6719 mL 47.3438 mL 118.3594 mL
    5 mM 0.9469 mL 4.7344 mL 9.4688 mL 23.6719 mL
    10 mM 0.4734 mL 2.3672 mL 4.7344 mL 11.8359 mL
    15 mM 0.3156 mL 1.5781 mL 3.1563 mL 7.8906 mL
    20 mM 0.2367 mL 1.1836 mL 2.3672 mL 5.9180 mL
    25 mM 0.1894 mL 0.9469 mL 1.8938 mL 4.7344 mL
    30 mM 0.1578 mL 0.7891 mL 1.5781 mL 3.9453 mL
    40 mM 0.1184 mL 0.5918 mL 1.1836 mL 2.9590 mL
    50 mM 0.0947 mL 0.4734 mL 0.9469 mL 2.3672 mL
    60 mM 0.0789 mL 0.3945 mL 0.7891 mL 1.9727 mL
    80 mM 0.0592 mL 0.2959 mL 0.5918 mL 1.4795 mL
    100 mM 0.0473 mL 0.2367 mL 0.4734 mL 1.1836 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Zalcitabine Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Zalcitabine7481-89-22',3'-Dideoxycytidine ddC DideoxycytidineHIVReverse TranscriptaseHuman immunodeficiency virusInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Zalcitabine
    製品番号:
    HY-17392
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.